Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kasugamycin, a new antibiotic.

Literature DB >> 5883494

Kasugamycin, a new antibiotic.

H Umezawa, M Hamada, Y Suhara, T Hashimoto, T Ikekawa.

Abstract

Entities: Chemical

Mesh：

Substances：
Anti-Bacterial Agents

Year: 1965 PMID： 5883494

Source DB: PubMed Journal: Antimicrob Agents Chemother (Bethesda)

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. The novel kasugamycin 2'-N-acetyltransferase gene aac(2')-IIa, carried by the IncP island, confers kasugamycin resistance to rice-pathogenic bacteria.

Authors: Atsushi Yoshii; Hiromitsu Moriyama; Toshiyuki Fukuhara
Journal: Appl Environ Microbiol Date: 2012-06-01 Impact factor: 4.792

Review 2. A comprehensive review of glycosylated bacterial natural products.

Authors: Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal: Chem Soc Rev Date: 2015-11-07 Impact factor: 54.564

3. Structural analysis of kasugamycin inhibition of translation.

Authors: Barbara S Schuwirth; J Michael Day; Cathy W Hau; Gary R Janssen; Albert E Dahlberg; Jamie H Doudna Cate; Antón Vila-Sanjurjo
Journal: Nat Struct Mol Biol Date: 2006-09-24 Impact factor: 15.369

4. Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis.

Authors: Jae-Hyun Lee; Chang-Min Lee; Joyce H Lee; Mun-Ock Kim; Jin Wook Park; Suchitra Kamle; Bedia Akosman; Erica L Herzog; Xue Yan Peng; Jack A Elias; Chun Geun Lee
Journal: Am J Respir Cell Mol Biol Date: 2022-09 Impact factor: 7.748

5. Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19.

Authors: Suchitra Kamle; Bing Ma; Chang Min Lee; Gail Schor; Yang Zhou; Chun Geun Lee; Jack A Elias
Journal: Elife Date: 2022-06-23 Impact factor: 8.713

6. ksgA mutations confer resistance to kasugamycin in Neisseria gonorrhoeae.

Authors: Paul M Duffin; H Steven Seifert
Journal: Int J Antimicrob Agents Date: 2008-12-18 Impact factor: 5.283

7. Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.

Authors: Ken-ichi Yoshida; Masanori Yamaguchi; Tetsuro Morinaga; Maya Ikeuchi; Masaki Kinehara; Hitoshi Ashida
Journal: Appl Environ Microbiol Date: 2006-02 Impact factor: 4.792